The basic conditions has changed and due to the current stock exchange developments it is not possible to carry out the deal.
Read more: AegirBio to acquire Dynamic Code
Photo of Anne Kihlgren, founder of Dynamic Code
Venture capital and creation firm Flagship Ventures has formed three new strategic partnerships withAstraZeneca, Nestlé Health Science and Bayer CropScience. Flagship, which manages $1.4 billion in capital, is perhaps best known for the eight successful IPOs it has backed in the past two years, as well as the formation of…
InDex Pharmaceuticals terminated a license agreement with Almirall S.A. involving the drug candidate Kappaproct® for the treatment of ulcerative colitis. The agreement had given Almirall licensed exclusive rights to Kappaproct® for the European market. Now InDex regains all worldwide development and commercialization rights for Kappaproct®, which is in late-stage clinical…
L2S AB, a life science company specialized in interactive cognitive behavioural therapy, has signed an international agreement with Pfizer. L2S, Learning 2 Sleep AB, is a Minc company based in Malmö with three part-owners. The company was founded in 2010 and provides services based on CBT treatment of sleeping disorders. One…
The Malmö based “micro-pharma” aiming at developing innovative new approaches to treat diabetes, PILA PHARMA has acquired XEN-D0501, a clinical ready and safe TRPV1 antagonist development candidate, previously owned by Ario Pharma. The acquired asset include a series of small molecule TRPV1 antagonists including the clinical ready and safe development candidate XEN-D0501, patents, know-how and data.…
